Oncotarget: Cancer Information Dissemination

Millions of people have already perished because of cancer. The disease has no cure, and scientists around the world are working together to discover the cure for the disease which claimed the lives of millions since the ancient times. Scientists are trying to test different treatments and techniques, hoping that one day, they will discover the right ingredient on how to stop the disease from developing and killing off the tumor that causes the disease to advance. Follow Oncotarget on Twitter. The discoveries of the scientists around the world are published online, and the most popular platform available today is Oncotarget. The online publication releases articles twice a week, and scientists who are working in the field of oncology are the ones uploading their discoveries and letting their colleagues read and review every detail. Oncotarget includes information about cancer in the beginning, but the publication shifted later on to add more disease. The first articles for the online medical journal were published in 2010, and a few years later on, more scientists around the world trust the online medical journal, and they are reading all of the information posted so that they can apply it with their patients too. Andrei V. Gudkov, and Dr. Mikhail Blagosklonny, two renowned oncologists working at the Roswell Park Cancer Institute are the online medical journal’s editors in chief. The hard copy version of the online medical journal is published in impact journals.

Listen: https://www.stitcher.com/podcast/oncotarget

Dr. Mikhail Blagosklonny is first known for his conquest to fight aging with the use of rapamycin. His discovery was also published in Oncotarget, and thousands of scientists from around the world have seen his research and commended him for its probability. Andrei V. Gudkov and Dr. Mikhail Blagosklonny are encouraging all of the oncologists around the world to try using the online medical journal that they created, and they are hoping that through this platform, information can freely flow among the scientists. Andrei V. Gudkov and Dr. Mikhail Blagosklonny hopes that the cure for cancer be developed as soon as possible so that they can save more lives and have a chance of extending the life of humans. Learn more at researchgate.net

How Clay Siegall has Revolutionized Cancer Treatment

Clay Siegall is the Chief Executive Officer and also the Founder of Seattle Genetics. He recently had an interview with Inspire where he talked about his life, company and how to become successful. According to Clay Siegall, cancer treatment has been made easier and efficient through targeted therapies and that the old systemic chemotherapies will soon be a thing of the past. Clay Siegall also says that targeted therapies are by far more tolerable compared to the traditional chemotherapies. Clay Siegall told Inspire that since he was young, he was intrigued by medicine, technology power and also the need to overcome the disease.

Clay Siegall became interested in the treatment of cancer while he was at the University of Maryland studying Zoology. This was a member of his family became sick from cancer and at one point developed anemia due to chemotherapy. This got Clay thinking of how to come up with better ways of cancer treatment. At first, Clay Siegall was not interested in the money part of it, but as the company grew, he started making money. Asked how Seattle Genetics makes money, Clay Siegall said that there are several ways the company makes money; by selling its own, proprietary drugs, revenues from production partnerships and also licensing of processes and technologies produced by the enterprise.

Clay Siegall says that hard work is what has led to his success. He also attributes his success to passion, great focus, networking, and discipline. He founded Seattle Genetics in 1998 and had ever since led the company to achieve a tremendous success and growth. The company is specialized in targeted therapy drugs development for diseases that have been unable to experience mortality improvements for many years. Dr. Clay studied at the University of Maryland where he acquired his BS in Zoology. He also got his Ph.D. in Genetics from the George Washington University.

Clay Siegall has managed to steer Seattle Genetics from a small startup to a huge company in the cancer research sector. His mission is to come up with drugs that will effectively prevent and treat cancer and also that are more tolerable to the patient while having minimal side effects.